Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Psychiatry
Published in: BMC Psychiatry 1/2013

Open Access 01-12-2013 | Research article

Self-Reported quality of life in adults with attention-deficit/hyperactivity disorder and executive function impairment treated with lisdexamfetamine dimesylate: a randomized, double-blind, multicenter, placebo-controlled, parallel-group study

Authors: Lenard A Adler, Bryan Dirks, Patrick Deas, Aparna Raychaudhuri, Matthew Dauphin, Keith Saylor, Richard Weisler

Published in: BMC Psychiatry | Issue 1/2013

Login to get access

Abstract

Background

This study examined the effects of lisdexamfetamine dimesylate (LDX) on quality of life (QOL) in adults with attention-deficit/hyperactivity disorder (ADHD) and clinically significant executive function deficits (EFD).

Methods

This report highlights QOL findings from a 10-week randomized placebo-controlled trial of LDX (30–70 mg/d) in adults (18–55 years) with ADHD and EFD (Behavior Rating Inventory of EF-Adult, Global Executive Composite [BRIEF-A GEC] ≥65). The primary efficacy measure was the self-reported BRIEF-A; a key secondary measure was self-reported QOL on the Adult ADHD Impact Module (AIM-A). The clinician-completed ADHD Rating Scale version IV (ADHD-RS-IV) with adult prompts and Clinical Global Impressions-Severity (CGI-S) were also employed. The Adult ADHD QoL (AAQoL) was added while the study was in progress. A post hoc analysis examined the subgroup having evaluable results from both AIM-A and AAQoL.

Results

Of 161 randomized (placebo, 81; LDX, 80), 159 were included in the safety population. LDX improved AIM-A multi-item domain scores versus placebo; LS mean difference for Performance and Daily Functioning was 21.6 (ES, 0.93, P<.0001); Impact of Symptoms: Daily Interference was 14.9 (ES, 0.62, P<.0001); Impact of Symptoms: Bother/Concern was 13.5 (ES, 0.57, P=.0003); Relationships/Communication was 7.8 (ES, 0.31, P=.0302); Living With ADHD was 9.1 (ES, 0.79, P<.0001); and General Well-Being was 10.8 (ES, 0.70, P<.0001). AAQoL LS mean difference for total score was 21.0; for subscale: Life Productivity was 21.0; Psychological Health was 12.1; Life Outlook was 12.5; and Relationships was 7.3. In a post hoc analysis of participants with both AIM-A and AAQoL scores, AIM-A multi-item subgroup analysis scores numerically improved with LDX, with smaller difference for Impact of Symptoms: Daily Interference. The safety profile of LDX was consistent with amphetamine use in previous studies.

Conclusions

Overall, adults with ADHD/EFD exhibited self-reported improvement on QOL, using the AIM-A and AAQoL scales in line with medium/large ES; these improvements were paralleled by improvements in EF and ADHD symptoms. The safety profile of LDX was similar to previous studies.

Trial registration

ClinicalTrials.gov, NCT01101022
Appendix
Available only for authorised users
Literature
1.
Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, Faraone SV, Greenhill LL, Howes MJ, Secnik K, et al: The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006, 163 (4): 716-723. 10.1176/appi.ajp.163.4.716.CrossRefPubMedPubMedCentral
2.
Brown TE: Executive functions and attention deficit hyperactivity disorder: implications of two conflicting views. Int J Disability Develop Educ. 2006, 53 (1): 35-46. 10.1080/10349120500510024.CrossRef
3.
Willcutt EG, Doyle AE, Nigg JT, Faraone SV, Pennington BF: Validity of the executive function theory of attention-deficit/hyperactivity disorder: a meta-analytic review. Biol Psychiatry. 2005, 57 (11): 1336-1346. 10.1016/j.biopsych.2005.02.006.CrossRefPubMed
4.
Castellanos FX, Sonuga-Barke EJ, Milham MP, Tannock R: Characterizing cognition in ADHD: beyond executive dysfunction. Trends Cogn Sci. 2006, 10 (3): 117-123. 10.1016/j.tics.2006.01.011.CrossRefPubMed
5.
Gioia GA, Isquith PK, Retzlaff PD, Espy KA: Confirmatory factor analysis of the Behavior Rating Inventory of Executive Function (BRIEF) in a clinical sample. Child Neuropsychol. 2002, 8 (4): 249-257. 10.1076/chin.8.4.249.13513.CrossRefPubMed
6.
Gioia GA, Isquith PK, Guy SC, Kenworthy L: BRIEF: Behavior Rating Inventory of Executive Function: Professional Manual. 2000, Lutz, FL: Psychological Assessment Resources, Inc
7.
Barkley RA: Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Psychol Bull. 1997, 121 (1): 65-94.CrossRefPubMed
8.
Lawrence V, Houghton S, Tannock R, Douglas G, Durkin K, Whiting K: ADHD outside the laboratory: boys’ executive function performance on tasks in videogame play and on a visit to the zoo. J Abnorm Child Psychol. 2002, 30 (5): 447-462. 10.1023/A:1019812829706.CrossRefPubMed
9.
Biederman J, Petty CR, Fried R, Doyle AE, Spencer T, Seidman LJ, Gross L, Poetzl K, Faraone SV: Stability of executive function deficits into young adult years: a prospective longitudinal follow-up study of grown up males with ADHD. Acta Psychiatr Scand. 2007, 116 (2): 129-136. 10.1111/j.1600-0447.2007.01008.x.CrossRefPubMed
10.
Biederman J, Petty CR, Doyle AE, Spencer T, Henderson CS, Marion B, Fried R, Faraone SV: Stability of executive function deficits in girls with ADHD: a prospective longitudinal followup study into adolescence. Dev Neuropsychol. 2008, 33 (1): 44-61.CrossRefPubMed
11.
Biederman J, Petty C, Fried R, Fontanella J, Doyle AE, Seidman LJ, Faraone SV: Impact of psychometrically defined deficits of executive functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry. 2006, 163 (10): 1730-1738. 10.1176/appi.ajp.163.10.1730.CrossRefPubMed
12.
Biederman J, Monuteaux MC, Doyle AE, Seidman LJ, Wilens TE, Ferrero F, Morgan CL, Faraone SV: Impact of executive function deficits and attention-deficit/hyperactivity disorder (ADHD) on academic outcomes in children. J Consult Clin Psychol. 2004, 72 (5): 757-766.CrossRefPubMed
13.
Brown TE: Brown Attention-Deficit Hyperactivity Disorder Scales for Adolescents and Adults. 1996, San Antonio, TX: The Psychological Corporation
14.
Barkley RA: Barkley Deficits in Executive Functioning Scale (BDEFS). 2011, New York, NY: The Guilford Press
15.
Roth RM, Isquith PK, Gioia GA: Behavior Rating Inventory of Executive Function - Adult Version (BRIEF-A). 1999, Lutz, FL: Psychological Assessment Resources, Inc.
16.
Shallice T, Burgess PW: Deficits in strategy application following frontal lobe damage in man. Brain. 1991, 114 (Pt 2): 727-741.CrossRefPubMed
17.
Barkley RA, Fischer M: Predicting impairment in major life activities and occupational functioning in hyperactive children as adults: self-reported executive function (EF) deficits versus EF tests. Dev Neuropsychol. 2011, 36 (2): 137-161. 10.1080/87565641.2010.549877.CrossRefPubMed
18.
Coghill D: The impact of medications on quality of life in attention-deficit hyperactivity disorder: a systematic review. CNS Drugs. 2010, 24 (10): 843-866. 10.2165/11537450-000000000-00000.CrossRefPubMed
19.
Adler LA, Spencer TJ, Levine LR, Ramsey JL, Tamura R, Kelsey D, Ball SG, Allen AJ, Biederman J: Functional outcomes in the treatment of adults with ADHD. J Atten Disord. 2008, 11 (6): 720-727.CrossRefPubMed
20.
Brown TE, Landgraf JM: Improvements in executive function correlate with enhanced performance and functioning and health-related quality of life: evidence from 2 large, double-blind, randomized, placebo-controlled trials in ADHD. Postgrad Med. 2010, 122 (5): 42-51. 10.3810/pgm.2010.09.2200.CrossRefPubMed
21.
Matza LS, Johnston JA, Faries DE, Malley KG, Brod M: Responsiveness of the Adult Attention-Deficit/Hyperactivity Disorder Quality of Life Scale (AAQoL). Qual Life Res. 2007, 16 (9): 1511-1520. 10.1007/s11136-007-9254-9.CrossRefPubMed
22.
Landgraf JM: Monitoring quality of life in adults with ADHD: reliability and validity of a new measure. J Atten Disord. 2007, 11 (3): 351-362. 10.1177/1087054707299400.CrossRefPubMed
23.
Spencer TJ, Landgraf JM, Adler LA, Weisler RH, Anderson CS, Youcha SH: Attention-deficit/hyperactivity disorder–specific quality of life with triple-bead mixed amphetamine salts (SPD465) in adults: results of a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2008, 69 (11): 1766-1775. 10.4088/JCP.v69n1112.CrossRefPubMed
24.
Brod M, Johnston J, Able S, Swindle R: Validation of the Adult Attention-Deficit/Hyperactivity Disorder Quality-of-Life Scale (AAQoL): a disease-specific quality-of-life measure. Qual Life Res. 2006, 15 (1): 117-129. 10.1007/s11136-005-8325-z.CrossRefPubMed
25.
Wayne PA: Vyvanse [package insert]. 2012, Wayne, PA: Shire US Inc
26.
Adler LA, Goodman DW, Kollins SH, Weisler RH, Krishnan S, Zhang Y, Biederman J on behalf of the 303 Study Group: Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2008, 69 (9): 1364-1373. 10.4088/JCP.v69n0903.CrossRefPubMed
27.
DuPaul GJ, Power TJ, Anastopoulos AD, Reid R: ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation. 1998, New York, NY: Guilford Press
28.
Adler L, Cohen J: Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am. 2004, 27 (2): 187-201. 10.1016/j.psc.2003.12.003.CrossRefPubMed
29.
Sandra Kooij JJ, Marije Boonstra A, Swinkels SH, Bekker EM, de Noord I, Buitelaar JK: Reliability, validity, and utility of instruments for self-report and informant report concerning symptoms of ADHD in adult patients. J Atten Disord. 2008, 11 (4): 445-458. 10.1177/1087054707299367.CrossRefPubMed
30.
Brown TE, Brams M, Gao J, Gasior M, Childress A: Open-label administration of lisdexamfetamine dimesylate improves executive function impairments and symptoms of attention-deficit/hyperactivity disorder in adults. Postgrad Med. 2010, 122 (5): 7-17. 10.3810/pgm.2010.09.2196.CrossRefPubMed
31.
Brams M, Giblin J, Gasior M, Gao J, Wigal T: Effects of open-label lisdexamfetamine dimesylate on self-reported quality of life in adults with ADHD. Postgrad Med. 2011, 123 (3): 99-108.CrossRefPubMed
32.
Adler LA, Dirks BL, Deas P, Raychaudhuri A, Dauphin MR, Lasser R, Weisler RH: Lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2013, 74 (7): 694-702. 10.4088/JCP.12m08144.CrossRefPubMed
33.
American Psychiatric Association: Attention-deficit and disruptive behavior disorders. Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR, Fourth Edition. Text Revision. 2000, Washington, DC: American Psychiatric Association, 85-93. FourthCrossRef
34.
35.
Guy W: Clinical global impressions. ECDEU Assessment Manual for Psychopharmacology. 1976, Rockville, MD: US Department of Health, Education, and Welfare; Public Health Service, Alcohol, Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch, 218-222.
36.
Barkley RA: Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002, 63 (Suppl 12): 10-15.PubMed
37.
Biederman J, Faraone SV: The effects of attention-deficit/hyperactivity disorder on employment and household income. MedGenMed. 2006, 8 (3): 12-PubMedPubMedCentral
38.
Kupper T, Haavik J, Drexler H, Ramos-Quiroga JA, Wermelskirchen D, Prutz C, Schauble B: The negative impact of attention-deficit/hyperactivity disorder on occupational health in adults and adolescents. Int Arch Occup Environ Health. 2012, 85 (8): 837-847. 10.1007/s00420-012-0794-0.CrossRefPubMed
39.
Spencer TJ, Adler LA, Weisler RH, Youcha SH: Triple-bead mixed amphetamine salts (SPD465), a novel, enhanced extended-release amphetamine formulation for the treatment of adults with ADHD: a randomized, double-blind, multicenter, placebo-controlled study. J Clin Psychiatry. 2008, 69 (9): 1437-1448. 10.4088/JCP.v69n0911.CrossRefPubMed
40.
Adler LA, Liebowitz M, Kronenberger W, Qiao M, Rubin R, Hollandbeck M, Deldar A, Schuh K, Durell T: Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder. Depress Anxiety. 2009, 26 (3): 212-221. 10.1002/da.20549.CrossRefPubMed
41.
Ramos-Quiroga JA, Casas M: Achieving remission as a routine goal of pharmacotherapy in attention-deficit hyperactivity disorder. CNS Drugs. 2011, 25 (1): 17-36. 10.2165/11538450-000000000-00000.CrossRefPubMed
Metadata
Title
Self-Reported quality of life in adults with attention-deficit/hyperactivity disorder and executive function impairment treated with lisdexamfetamine dimesylate: a randomized, double-blind, multicenter, placebo-controlled, parallel-group study
Authors
Lenard A Adler
Bryan Dirks
Patrick Deas
Aparna Raychaudhuri
Matthew Dauphin
Keith Saylor
Richard Weisler
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2013
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/1471-244X-13-253

Other articles of this Issue 1/2013

BMC Psychiatry 1/2013 Go to the issue

Correspondence

Occupational issues of adults with ADHD

Editorial

Resistance to treatment in eating disorders: a critical challenge

Research article

Integrating mobile-phone based assessment for psychosis into people’s everyday lives and clinical care: a qualitative study

Research article

Predictors of psychiatric hospitalization during 6 months of maintenance treatment with olanzapine long-acting injection: post hoc analysis of a randomized, double-blind study

Study protocol

Expectations, experiences and attitudes of patients and primary care health professionals regarding online psychotherapeutic interventions for depression: protocol for a qualitative study

Study protocol

The E Sibling Project – exploratory randomised controlled trial of an online multi-component psychoeducational intervention for siblings of individuals with first episode psychosis